Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

Michael Birrer to Transfection

This is a "connection" page, showing publications Michael Birrer has written about Transfection.

 
Connection Strength
 
 
 
0.665
 
  1. Leaner VD, Chick JF, Donninger H, Linniola I, Mendoza A, Khanna C, Birrer MJ. Inhibition of AP-1 transcriptional activity blocks the migration, invasion, and experimental metastasis of murine osteosarcoma. Am J Pathol. 2009 Jan; 174(1):265-75.
    View in: PubMed
    Score: 0.077
  2. Katabami M, Donninger H, Hommura F, Leaner VD, Kinoshita I, Chick JF, Birrer MJ. Cyclin A is a c-Jun target gene and is necessary for c-Jun-induced anchorage-independent growth in RAT1a cells. J Biol Chem. 2005 Apr 29; 280(17):16728-38.
    View in: PubMed
    Score: 0.059
  3. Kinoshita I, Leaner V, Katabami M, Manzano RG, Dent P, Sabichi A, Birrer MJ. Identification of cJun-responsive genes in Rat-1a cells using multiple techniques: increased expression of stathmin is necessary for cJun-mediated anchorage-independent growth. Oncogene. 2003 May 08; 22(18):2710-22.
    View in: PubMed
    Score: 0.052
  4. Roane BM, Meza-Perez S, Katre AA, Goldsberry WN, Randall TD, Norian LA, Birrer MJ, Arend RC. Neutralization of TGF? Improves Tumor Immunity and Reduces Tumor Progression in Ovarian Carcinoma. Mol Cancer Ther. 2021 03; 20(3):602-611.
    View in: PubMed
    Score: 0.044
  5. Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, Birrer MJ. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene. 1999 Oct 28; 18(44):6063-70.
    View in: PubMed
    Score: 0.041
  6. Szabo E, Francis J, Birrer MJ. Alterations in differentiation and apoptosis induced by bufalin in cJun overexpressing U-937 cells. Int J Oncol. 1998 Feb; 12(2):403-9.
    View in: PubMed
    Score: 0.036
  7. Szabo E, Preis LH, Birrer MJ. Constitutive cJun expression induces partial macrophage differentiation in U-937 cells. Cell Growth Differ. 1994 Apr; 5(4):439-46.
    View in: PubMed
    Score: 0.028
  8. Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin ZC, Li T, Hua X, Landen CN, Birrer MJ, S?nchez-Beato M, Zhang R. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK. Mol Cancer Res. 2012 Nov; 10(11):1462-72.
    View in: PubMed
    Score: 0.025
  9. Permuth-Wey J, Kim D, Tsai YY, Lin HY, Chen YA, Barnholtz-Sloan J, Birrer MJ, Bloom G, Chanock SJ, Chen Z, Cramer DW, Cunningham JM, Dagne G, Ebbert-Syfrett J, Fenstermacher D, Fridley BL, Garcia-Closas M, Gayther SA, Ge W, Gentry-Maharaj A, Gonzalez-Bosquet J, Goode EL, Iversen E, Jim H, Kong W, McLaughlin J, Menon U, Monteiro AN, Narod SA, Pharoah PD, Phelan CM, Qu X, Ramus SJ, Risch H, Schildkraut JM, Song H, Stockwell H, Sutphen R, Terry KL, Tyrer J, Vierkant RA, Wentzensen N, Lancaster JM, Cheng JQ, Sellers TA. LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res. 2011 Jun 01; 71(11):3896-903.
    View in: PubMed
    Score: 0.023
  10. Dosaka-Akita H, Rosenberg RK, Minna JD, Birrer MJ. A complex pattern of translational initiation and phosphorylation in L-myc proteins. Oncogene. 1991 Mar; 6(3):371-8.
    View in: PubMed
    Score: 0.022
  11. Birrer MJ, Raveh L, Dosaka H, Segal S. A transfected L-myc gene can substitute for c-myc in blocking murine erythroleukemia differentiation. Mol Cell Biol. 1989 Jun; 9(6):2734-7.
    View in: PubMed
    Score: 0.020
  12. Wang B, Khachigian LM, Esau L, Birrer MJ, Zhao X, Parker MI, Hendricks DT. A key role for early growth response-1 and nuclear factor-kappaB in mediating and maintaining GRO/CXCR2 proliferative signaling in esophageal cancer. Mol Cancer Res. 2009 May; 7(5):755-64.
    View in: PubMed
    Score: 0.020
  13. Sch?tte J, Minna JD, Birrer MJ. Deregulated expression of human c-jun transforms primary rat embryo cells in cooperation with an activated c-Ha-ras gene and transforms rat-1a cells as a single gene. Proc Natl Acad Sci U S A. 1989 Apr; 86(7):2257-61.
    View in: PubMed
    Score: 0.020
  14. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008 Dec 18; 359(25):2641-50.
    View in: PubMed
    Score: 0.019
  15. Irarrazabal CE, Williams CK, Ely MA, Birrer MJ, Garcia-Perez A, Burg MB, Ferraris JD. Activator protein-1 contributes to high NaCl-induced increase in tonicity-responsive enhancer/osmotic response element-binding protein transactivating activity. J Biol Chem. 2008 Feb 01; 283(5):2554-63.
    View in: PubMed
    Score: 0.018
  16. Tsuda H, Ito YM, Ohashi Y, Wong KK, Hashiguchi Y, Welch WR, Berkowitz RS, Birrer MJ, Mok SC. Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6880-8.
    View in: PubMed
    Score: 0.015
  17. Elam C, Hesson L, Vos MD, Eckfeld K, Ellis CA, Bell A, Krex D, Birrer MJ, Latif F, Clark GJ. RRP22 is a farnesylated, nucleolar, Ras-related protein with tumor suppressor potential. Cancer Res. 2005 Apr 15; 65(8):3117-25.
    View in: PubMed
    Score: 0.015
  18. Kielosto M, Nummela P, Katainen R, Leaner V, Birrer MJ, H?ltt? E. Reversible regulation of the transformed phenotype of ornithine decarboxylase- and ras-overexpressing cells by dominant-negative mutants of c-Jun. Cancer Res. 2004 Jun 01; 64(11):3772-9.
    View in: PubMed
    Score: 0.014
  19. Shen YH, Godlewski J, Zhu J, Sathyanarayana P, Leaner V, Birrer MJ, Rana A, Tzivion G. Cross-talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors. J Biol Chem. 2003 Jul 18; 278(29):26715-21.
    View in: PubMed
    Score: 0.013
  20. Fan M, Goodwin ME, Birrer MJ, Chambers TC. The c-Jun NH(2)-terminal protein kinase/AP-1 pathway is required for efficient apoptosis induced by vinblastine. Cancer Res. 2001 Jun 01; 61(11):4450-8.
    View in: PubMed
    Score: 0.011
  21. Vos MD, Ellis CA, Bell A, Birrer MJ, Clark GJ. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem. 2000 Nov 17; 275(46):35669-72.
    View in: PubMed
    Score: 0.011
  22. Paasinen-Sohns A, Kielosto M, K??ri?inen E, Eloranta T, Laine A, J?nne OA, Birrer MJ, H?ltt? E. c-Jun activation-dependent tumorigenic transformation induced paradoxically by overexpression or block of S-adenosylmethionine decarboxylase. J Cell Biol. 2000 Nov 13; 151(4):801-10.
    View in: PubMed
    Score: 0.011
  23. Wang N, Verna L, Hardy S, Zhu Y, Ma KS, Birrer MJ, Stemerman MB. c-Jun triggers apoptosis in human vascular endothelial cells. Circ Res. 1999 Sep 03; 85(5):387-93.
    View in: PubMed
    Score: 0.010
  24. Smith LM, Birrer MJ, Stampfer MR, Brown PH. Breast cancer cells have lower activating protein 1 transcription factor activity than normal mammary epithelial cells. Cancer Res. 1997 Jul 15; 57(14):3046-54.
    View in: PubMed
    Score: 0.009
  25. Zhao B, Yu W, Qian M, Simmons-Menchaca M, Brown P, Birrer MJ, Sanders BG, Kline K. Involvement of activator protein-1 (AP-1) in induction of apoptosis by vitamin E succinate in human breast cancer cells. Mol Carcinog. 1997 Jul; 19(3):180-90.
    View in: PubMed
    Score: 0.009
  26. Pisegna JR, Leyton J, Coelho T, Hida T, Jakowlew S, Birrer M, Fridkin M, Gozes I, Moody TW. PACAP hybrid: a new PACAP receptor antagonist. Life Sci. 1997; 61(6):631-9.
    View in: PubMed
    Score: 0.008
  27. Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S, Birrer MJ, Szabo E, Zon LI, Kyriakis JM, Haimovitz-Friedman A, Fuks Z, Kolesnick RN. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature. 1996 Mar 07; 380(6569):75-9.
    View in: PubMed
    Score: 0.008
  28. Lengye E, Singh B, Gum R, Nerlov C, Sabichi A, Birrer M, Boyd D. Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene. Oncogene. 1995 Dec 21; 11(12):2639-48.
    View in: PubMed
    Score: 0.008
  29. Watts RG, Ben-Ari ET, Bernstein LR, Birrer MJ, Winterstein D, Wendel E, Colburn NH. c-jun and multistage carcinogenesis: association of overexpression of introduced c-jun with progression toward a neoplastic endpoint in mouse JB6 cells sensitive to tumor promoter-induced transformation. Mol Carcinog. 1995 May; 13(1):27-36.
    View in: PubMed
    Score: 0.007
  30. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci U S A. 1994 Jan 18; 91(2):609-13.
    View in: PubMed
    Score: 0.007
  31. Bar-Ner M, Messing LT, Cultraro CM, Birrer MJ, Segal S. Regions within the c-Myc protein that are necessary for transformation are also required for inhibition of differentiation of murine erythroleukemia cells. Cell Growth Differ. 1992 Mar; 3(3):183-90.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.